The FDA's new AI assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Chart Industries, Inc. (NYSE: GTLS) and Flowserve Corporation (NYSE: FLS) today announced that they have entered into a definitive agreement to combine in an all-stock merger of equals, creating a ...

Background and objective Prior studies have suggested that patients with premature ventricular complexes (PVCs) may have an ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

Hypertension is the most common cardiovascular risk factor. 13 Hypertension is found in 35% to 55% of patients when they are diagnosed with PAD. 14 Additionally, hypertension has been associated with ...

For this reason, routine pretreatment in patients undergoing an early invasive management strategy (<24 hours) is not supported by clinical trial data. However, it may be reasonable to consider ...

Objectives Data linkage of cohort-based data and electronic health records (EHRs) has been practised in many countries, but in Hong Kong there is still a lack of such research. To expand the use of ...

To gain a competitive edge with AI, healthcare companies should reclassify their data in a uniform way and upskill staff, ...

Enterprise data management (EDM) is the framework organizations use to manage data across systems, teams and workflows. It ...

Claude Price is VP & global head of clinical data management at Quanticate. He has over 18 years’ experience within clinical research, covering roles in both CDM and project management.